about
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapySuccessful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up.Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.Primary Linitis Plastica of the Rectum: Focus on Magnetic Resonance Imaging Patterns and Treatment Options.Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study.Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice.Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas.St. Louis encephalitis in Argentina: the first case reported in the last seventeen years.Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease.Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.Metronomic cyclophosphamide: an alternative treatment for hepatic epithelioid hemangioendothelioma.Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.A new anti-mesothelin antibody targets selectively the membrane-associated form.SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.Evaluation of a 36 Gy elective node irradiation dose in anal cancer.[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer[Immunotherapy: an emerging strategies against prostate castration resistant cancer]Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer[Lung cancer in nonsmoker: a separate entity]Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerPerioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinomaA simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasmaIn situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trialDocetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study
P50
Q33417019-E82F4C42-E478-4F9D-BBE4-F335716B0B98Q33821465-DAA3BDB4-3785-47E2-9E88-4C33ED01D84DQ34982545-27BDFE6A-1842-4CE7-843F-45DBB7202558Q35076861-12CF194B-126D-4080-8B17-025888C99BDFQ36023783-ADB219E5-A96B-4AF0-A527-1C38EBA0F8FBQ36174677-289791E1-45F6-438D-AAED-66EB966813BBQ36724011-ED05FC9A-E40A-4C29-BD1C-D63547D92AC9Q37066657-14895FEF-3A38-42CA-A466-2D2A8888331BQ38077764-7F8FA8DC-5FFE-40D8-8688-DE6150BEF831Q41541911-352CE11B-76EB-4AB7-85E0-76ADFDD3F31BQ41746646-AD99F813-4F01-4ECB-8634-1F30775A24E1Q42263385-4A30B665-B80C-4480-AE41-58557C8FC6B6Q42540217-591F1107-6FE1-4FB9-9E3B-CAA8EAB7DB55Q42734899-07288B5D-B058-40E6-B8AE-57FDC4492196Q43078253-3EDD9DC8-D113-442A-AD52-766AA3854301Q44586433-183E0DF6-3368-400C-8852-51D0BBA634E8Q45412333-98C55D63-41DA-4BD0-8917-DCA64F6FC06EQ48136626-B987840A-6635-4162-A66F-ACE41357481FQ51082110-85670EBC-E373-4917-8C1A-A5A83FB91B92Q52597548-B98F9ED4-EC1F-4583-B9A3-99261611C234Q53378261-B2ECF41C-D2E0-4AF6-82B1-D0635846FE69Q53829222-720B71DF-4E56-4897-BB8B-3939C659D9ADQ54175821-8385903B-0D0F-47B5-A506-BF7902A00E18Q58739971-F376B0E9-87AC-454B-A302-834BC866DFEEQ83933192-7CFA8A2D-FAAE-44FE-BBD3-FABBD772D95AQ85199265-7411F084-51F3-468B-8306-6BE1F2BE2B75Q85767271-1D6AE198-18F0-4F03-A61A-0DDDC07497FCQ87869327-BBFD47DC-EA62-4F7D-8463-2B4C2D0BD513Q87922198-A7170EB6-AD66-49A4-A4C3-EFA4E51DB007Q88341492-5750E85F-694A-4B28-ACF0-215F3DAD3EAAQ88550364-9EF36AA7-C9CD-4900-8A51-A0FFB0DA1633Q90450359-1BB1581B-D313-40B5-AA81-55F86EEB7933
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stefano Kim
@ast
Stefano Kim
@en
Stefano Kim
@es
Stefano Kim
@nl
Stefano Kim
@sl
type
label
Stefano Kim
@ast
Stefano Kim
@en
Stefano Kim
@es
Stefano Kim
@nl
Stefano Kim
@sl
prefLabel
Stefano Kim
@ast
Stefano Kim
@en
Stefano Kim
@es
Stefano Kim
@nl
Stefano Kim
@sl
P106
P1153
46261294100
P21
P31
P496
0000-0003-2851-7119